Moshe Spinowitz

Mr. Spinowitz regularly advises multinational companies on the restructuring of their operations, including integration following large cross-border acquisitions. He also counsels pharmaceutical and technology companies in connection with the structuring of their intellectual property holdings, as well as a variety of companies in connection with U.S. and international tax law developments.

Select representations include:

• Vertex Pharmaceuticals in its $4.9 billion acquisition of Alpine Immune Sciences
• Mirati Therapeutics in its $4.8 billion acquisition by Bristol Myers Squibb
• Ambrx Biopharma in its redomiciliation to the U.S. and its $2 billion acquisition by Johnson & Johnson
• Dicerna Pharmaceuticals in its $3.3 billion acquisition by Novo Nordisk
• L’Occitane International in its acquisition of Sol de Janeiro Holdings
• ArQule, Inc. in its $2.7 billion acquisition by a subsidiary of Merck & Co., Inc.
• Juno Therapeutics in its $9 billion acquisition by Celgene
• Gilead Sciences, Inc. in its $11.9 billion acquisition of Kite Pharma, its acquisition of Cell Design Labs for up to $567 million, and its research and development collaboration with, and equity investment in, Galapagos NV
• Biogen Inc. in the spin-off of its hemophilia business as an independent public company called Bioverativ
• Konecranes plc in its acquisition of Terex Corporation’s material handling and port solutions unit for $1.28 billion
• Spectra Energy Corp in its combination with Enbridge Inc. for $28 billion
• Morphosys in its $2.9 billion acquisition by Novartis and simultaneous disposition of Monjuvi to Incyte
• EyeBio in its acquisition by Merck for a $1.3 billion upfront payment and up to $1.7 billion in future milestone payments equaling a potential value of $3 billion
• CureVac in its pending $1.25 billion acquisition by BioNTech
• SiteOne in its pending $1 billion acquisition by Eli Lilly
• Chimerix in its $935 million acquisition by Jazz Pharmaceuticals
• Evergreen Theragnositcs in its acquisition by Lantheus Holdings for $250 million upfront and up to $753 million in future milestone payments
• BioCryst in the sale of its European ORLADEYO business to Neopharmed Gentili for $250 million upfront and up to $14 million in future milestone payments

In recognition of his work, Mr. Spinowitz has been named one of Massachusetts Lawyers Weekly’s Go To Lawyers for Taxation and repeatedly selected for inclusion in Chambers USA. Additionally, he has been recognized as one of Lawdragon’s 500 Leading Global Tax Lawyers and in Best Lawyers in America in the Tax Law category. He also was named as a recipient of Bloomberg’s Tax Portfolio Author of the Year Award for his work on the Bloomberg Tax portfolio “Outbound Tax Planning for U.S. Multinational Corporations (Portfolio 6380).” Prior to joining Skadden, he served as a law clerk to Judge Michael Boudin on the U.S. Court of Appeals for the First Circuit, and Justice Antonin Scalia on the U.S. Supreme Court.